The Next Step of Their Control Is Here …

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

Steve Glover Biography and Net Worth

Director of PDS Biotechnology

Mr. Glover joined PDS Biotech’s Board of Directors in April 2019 and is the Chairman of the Board of Directors. Mr. Glover is the Co-Founder and Managing Principal for Asclepius Life Sciences Fund, LP, and the Co-Founder, President and CEO of ZyVersa Therapeutics (formerly Variant Pharmaceuticals), a clinical-stage specialty biopharmaceutical company focused on developing drugs to treat inflammatory and renal diseases. Mr. Glover has extensive experience executing biopharmaceutical company turnarounds and growing top line revenues, with a focus on pharmaceutical business strategy corporate development, product development, commercialization and business optimization. His vast experience spans Fortune 100, start up and entrepreneurial environments. Mr. Glover transaction experience covers over 25 transactions totaling over $10 billion. His strategic and operational experience, which covers most therapeutic classes of biopharmaceuticals, includes strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management. Prior to co-founding ZyVersa, Mr. Glover was Co-Founder and Chief Business Officer of Coherus BioSciences, a late-stage commercial biologics platform company focused on delivering biosimilar therapeutics which went public in 2014. Previously, he was President of Insmed Therapeutic Proteins and EVP and Chief Business Officer of Insmed Incorporated, where he was responsible for the creation of the Company’s biosimilar business unit and divestiture of that business to Merck and led the strategic review process that resulted in the merger of Insmed and Transave. Prior to joining Insmed, Mr. Glover held senior-level positions in sales, marketing and operations at Andrx Corporation, Roche Laboratories, Amgen and IMS Health. He currently serves as a Director of ZyVersa Therapeutics, Incon and Asclepius, as well as a BOD member of the Coulter Foundation as the University of Miami U Innovation Life Sciences Office. He holds a Bachelor’s Degree in Marketing from Illinois State University.

What is Steve C. Glover's net worth?: The estimated net worth of Steve C. Glover is at least $208,593.30 as of June 15th, 2021. Mr. Glover owns 63,790 shares of PDS Biotechnology stock worth more than $208,593 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Glover may own. Learn More about Steve C. Glover's net worth.
How do I contact Steve C. Glover?: The corporate mailing address for Mr. Glover and other PDS Biotechnology executives is 25B Vreeland Road, Florham Park NJ, 07932. PDS Biotechnology can also be reached via phone at (800) 208-3343 and via email at [email protected]. Learn More on Steve C. Glover's contact information.
Has Steve C. Glover been buying or selling shares of PDS Biotechnology?: Steve C. Glover has not been actively trading shares of PDS Biotechnology during the past quarter. Most recently, on Tuesday, June 15th, Steve C. Glover bought 5,882 shares of PDS Biotechnology stock. The stock was acquired at an average cost of $8.50 per share, with a total value of $49,997.00. Following the completion of the transaction, the director now directly owns 63,790 shares of the company's stock, valued at $542,215. Learn More on Steve C. Glover's trading history.
Who are PDS Biotechnology's active insiders?: PDS Biotechnology's insider roster includes Steve Glover (Director), Matthew Hill (CFO), and Seth Van Voorhees (CFO). Learn More on PDS Biotechnology's active insiders.

Steve C. Glover Insider Trading History at PDS Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/15/2021	Buy	5,882	$8.50	$49,997.00	63,790

Steve C. Glover Buying and Selling Activity at PDS Biotechnology

PDS Biotechnology Company Overview

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Today's Range

Now: $3.27

$3.20

$3.38

50 Day Range

MA: $4.40

$2.65

$6.59

2 Week Range

Now: $3.27

$2.59

$10.27

Volume

415,643 shs

Average Volume

866,273 shs

Market Capitalization

$119.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67